184 related articles for article (PubMed ID: 26950068)
1. The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization.
Stamelos VA; Fisher N; Bamrah H; Voisey C; Price JC; Farrell WE; Redman CW; Richardson A
PLoS One; 2016; 11(3):e0150696. PubMed ID: 26950068
[TBL] [Abstract][Full Text] [Related]
2. Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells.
Yu L; Wu WK; Gu C; Zhong D; Zhao X; Kong Y; Lin Q; Chan MT; Zhou Z; Liu S
Oncotarget; 2016 Mar; 7(12):14693-707. PubMed ID: 26910910
[TBL] [Abstract][Full Text] [Related]
3. Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis.
Champa D; Orlacchio A; Patel B; Ranieri M; Shemetov AA; Verkhusha VV; Cuervo AM; Di Cristofano A
Oncotarget; 2016 Jun; 7(23):34453-71. PubMed ID: 27144341
[TBL] [Abstract][Full Text] [Related]
4. Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators.
Steele TM; Talbott GC; Sam A; Tepper CG; Ghosh PM; Vinall RL
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875757
[TBL] [Abstract][Full Text] [Related]
5. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.
Brem EA; Thudium K; Khubchandani S; Tsai PC; Olejniczak SH; Bhat S; Riaz W; Gu J; Iqbal A; Campagna R; Knight J; Mavis C; Hoskin P; Deeb G; Gibbs JF; Fetterly G; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2011 Jun; 153(5):599-611. PubMed ID: 21492126
[TBL] [Abstract][Full Text] [Related]
6. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling.
Koehler BC; Jassowicz A; Scherr AL; Lorenz S; Radhakrishnan P; Kautz N; Elssner C; Weiss J; Jaeger D; Schneider M; Schulze-Bergkamen H
BMC Cancer; 2015 Nov; 15():919. PubMed ID: 26585594
[TBL] [Abstract][Full Text] [Related]
7. A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells.
Smoot RL; Blechacz BR; Werneburg NW; Bronk SF; Sinicrope FA; Sirica AE; Gores GJ
Cancer Res; 2010 Mar; 70(5):1960-9. PubMed ID: 20160031
[TBL] [Abstract][Full Text] [Related]
8. Single-agent obatoclax (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells.
Yazbeck VY; Li C; Grandis JR; Zang Y; Johnson DE
Oral Oncol; 2014 Feb; 50(2):120-7. PubMed ID: 24216166
[TBL] [Abstract][Full Text] [Related]
9. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells.
Pérez-Galán P; Roué G; López-Guerra M; Nguyen M; Villamor N; Montserrat E; Shore GC; Campo E; Colomer D
Leukemia; 2008 Sep; 22(9):1712-20. PubMed ID: 18596739
[TBL] [Abstract][Full Text] [Related]
10. Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells.
Or CR; Chang Y; Lin WC; Lee WC; Su HL; Cheung MW; Huang CP; Ho C; Chang CC
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28035994
[TBL] [Abstract][Full Text] [Related]
11. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
[TBL] [Abstract][Full Text] [Related]
12. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.
Tang Y; Hamed HA; Cruickshanks N; Fisher PB; Grant S; Dent P
Mol Pharmacol; 2012 Apr; 81(4):527-40. PubMed ID: 22219388
[TBL] [Abstract][Full Text] [Related]
13. Autophagy contributes to modulating the cytotoxicities of Bcl-2 homology domain-3 mimetics.
Yu L; Liu S
Semin Cancer Biol; 2013 Dec; 23(6 Pt B):553-60. PubMed ID: 24012660
[TBL] [Abstract][Full Text] [Related]
14. Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects.
Opydo-Chanek M; Gonzalo O; Marzo I
Biochem Pharmacol; 2017 Jul; 136():12-23. PubMed ID: 28288819
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis.
Harnett CC; Abusneina A; Clément J; Gauthier ER
Cell Biochem Funct; 2015 Jul; 33(5):334-40. PubMed ID: 26178811
[TBL] [Abstract][Full Text] [Related]
16. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
Abed MN; Abdullah MI; Richardson A
J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
[TBL] [Abstract][Full Text] [Related]
17. BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma.
Lieber J; Ellerkamp V; Vogt F; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
Exp Cell Res; 2014 Mar; 322(1):217-25. PubMed ID: 24355809
[TBL] [Abstract][Full Text] [Related]
18. The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.
Lieber J; Armeanu-Ebinger S; Fuchs J
Int J Mol Sci; 2015 Feb; 16(2):4190-208. PubMed ID: 25690034
[TBL] [Abstract][Full Text] [Related]
19. Obatoclax induces Beclin 1- and ATG5-dependent apoptosis and autophagy in adenoid cystic carcinoma cells.
Liang LZ; Ma B; Liang YJ; Liu HC; Zhang TH; Zheng GS; Su YX; Liao GQ
Oral Dis; 2015 May; 21(4):470-7. PubMed ID: 25482163
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside.
Vela L; Marzo I
Curr Opin Pharmacol; 2015 Aug; 23():74-81. PubMed ID: 26079328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
